Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VBC117
- Development stage
- Phase 2
- Lead developer
- Velavigo Shanghai Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VBC117 is a first-in-class bispecific antibody-drug conjugate (ADC) that simultaneously targets the Epidermal Growth Factor Receptor (EGFR) and Cadherin-17 (CDH17). Developed by VelaVigo Bio, this therapeutic candidate is designed to treat advanced malignant solid tumors by selectively delivering a cytotoxic payload to cancer cells that co-express both antigens. EGFR is a well-validated oncogenic driver in various cancers, while CDH17 is a cell adhesion protein specifically overexpressed in gastrointestinal malignancies such as colorectal and gastric cancers. By utilizing a bispecific format, VBC117 aims to enhance tumor-specific binding and internalization, potentially reducing the systemic toxicities often associated with monospecific EGFR-targeted therapies. The drug is currently undergoing evaluation in a Phase 1/2a first-in-human clinical trial to assess its safety, tolerability, and preliminary efficacy in patients with refractory solid tumors.
- Other names
- VBC117VBC-117VBC 117
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)CDH17 (Cadherin-17)
Beyond the preview
Go deeper on VBC117.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VBC117.